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Abstract
Background. Kidney transplantation is believed to im-
prove health-related quality of life (HRQoL) of patients re-
quiring renal replacement therapy (RRT). Recent studies
suggested that the observed difference in HRQoL between
kidney transplant recipients (Tx) vs patients treated with
dialysis may reflect differences in patient characteristics.
We tested if Tx patients have better HRQoL compared to
waitlisted (WL) patients treated with dialysis after exten-
sive adjustment for covariables.
Methods. Eight hundred and eighty-eight prevalent Tx pa-
tients followed at a single outpatient transplant clinic and
187 WL patients treated with maintenance dialysis in nine
dialysis centres were enrolled in this observational cross-
sectional study. Data about socio-demographic and clinical
parameters, self-reported depressive symptoms and the
most frequent sleep disorders assessed by self-reported
questionnaires were collected at enrolment. HRQoL was
assessed by the Kidney Disease Quality of Life Question-
naire.
Results. Patient characteristics were similar in the Tx vs
WL groups: the proportion of males (58 vs 60%), mean ±
SD age (49 ± 13 vs 49 ± 12) and proportion of diabetics
(17 vs 18%), respectively, were all similar. Tx patients had
significantly better HRQoL scores compared to the WL
group both in generic (Physical function, General health
perceptions, Energy/fatigue, Emotional well-being) and
in kidney disease-specific domains (Symptoms/problems,
Effect- and Burden of kidney disease and Sleep). In multi-
variate regression models adjusting for clinical and socio-
demographic characteristics, sleep disorders and depressive
symptoms, the modality of RRT (WL vs Tx) remained inde-
pendently associated with three (General health percep-
tions, Effect- and Burden of kidney disease) out of the
eight HRQoL dimensions analysed.
Conclusions.Kidney Tx recipients have significantly better
HRQoL compared to WL dialysis patients in some, but not
all, dimensions of quality of life after accounting for differ-
ences in patient characteristics. Utilizing multidimensional
disease-specific questionnaires will allow better under-
standing of treatment, disease and patient-related factors po-
tentially affecting quality of life in patients with chronic
medical conditions.
Keywords: depression; dialysis; health-related quality of life; kidney
transplantation; sleep disorders
Introduction
Patients with advanced chronic kidney disease (CKD) re-
quiring renal replacement therapy (RRT) have impaired
health-related quality of life (HRQoL) [1–4]. Socio-
demographic (age, gender, education, income) and clinical
parameters (duration of renal disease, comorbid condi-
tions, haemoglobin (Hb), serum albumin, etc.) as well
as psychological factors (personality characteristics, de-
pression and anxiety, etc.) are reportedly associated with
HRQoL [5–10]. Furthermore, sleep disorders, which are
very common in patients with CKD, are also important
predictors of poor HRQoL in this patient population
[3,11–13].
Successful kidney transplantation (Tx) is the preferred
RRT for many patients with advanced CKD since it offers
longer survival and less morbidity than dialysis. It is also
believed to improve quality of life [7,9,14–16]. Most stud-
ies comparing HRQoL between patients after Tx vs on
maintenance dialysis, however, involved only limited num-
ber of participants and assessed only a few covariables. Fur-
thermore, many studies compared Tx patients to unselected
patients on dialysis with significantly different characteris-
tics.Frequently, those differences were not appropriately
accounted for as recently pointed out by several authors
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[6,17–19]. In a recent study, in which Tx patients were
compared to matched (age, gender and comorbidity)
waitlisted (WL) dialysis patients, no difference in per-
ceived health status (SF-36 scores) was found [19]. Final-
ly, the potential association between psycho-social
characteristics and sleep disorders vs HRQoL has largely
been neglected; only a few recent studies considered
those associations in their analyses [8,11,20,21]. Thus,
considerable uncertainty remains as to the difference in
quality of life of dialysis patients vs Tx patients when
appropriately adjusted for covariates.
Many of the cited studies utilized the SF-36 question-
naire, a generic instrument. Since many of the factors
associated with impaired HRQoL in patients with
CKD are closely related to the kidney disease, disease-
specific instruments may provide a better understanding
about the potential differences of HRQoL across treatment
modalities.
Based on the above considerations, we wanted to com-
pare HRQoL between waitlisted patients requiring mainten-
ance dialysis (WL) vs a large prevalent cohort of stable
kidney transplant recipients (Tx) using the Kidney Disease
Quality of Life-SF (KDQoL-SF) [22,23] questionnaire
which includes the SF-36 instrument and 11 kidney dis-
ease-targeted sub-scales. We collected information about a
large number of socio-demographic and clinical variables,
assessed depressive symptoms and self-reported data about
the presence of the most frequent sleep disorders [insomnia,
restless legs syndrome (RLS) and obstructive sleep apnoea
(OSA)]. This information was used to adjust for differences
in these variables between the Tx andWL samples in multi-
variate analyses. We hypothesized that Tx patients will have
better HRQoL compared to WL patients but this difference
will be attenuated after adjustment for clinical variables,
depressive symptoms and sleep disorders. We expected
that the differences would be more consistent on the kidney
disease-targeted sub-scales.
Materials and methods
Sample of patients and data collection
This prevalent cohort of stable kidney-transplanted patients (Tx) was se-
lected by inviting all patients 18 years or older (n = 1067) who were regu-
larly followed at a single kidney transplant outpatient clinic at the
Department of Transplantation and Surgery at Semmelweis University,
Budapest on 30 June 2002, to participate in our cross-sectional study
(Transplantation and Quality of Life-Hungary Study, TransQoL-HU
Study) [12,24–27]. All patients received renal transplant between 1977
and 2002. We also approached all WL dialysis patients (n = 214) (WL),
who were listed with the above transplant centre on 30 June 2002, and
had been receiving dialysis for at least 1 month in any of the nine
dialysis centres in Budapest. Data were collected between August
2002 and February 2003. Patients who had had transplantation, an acute
rejection or infection within 1 month of the data collection, had dementia
(determined by their most responsible physician) or refused to participate
were excluded.
Demographic information and details of medical history were col-
lected at enrolment when information about age, sex, aetiology of
CKD, the presence or absence of diabetes and other comorbidities were
obtained. Other socio-demographic parameters also collected were level
of education, employment status (full-time or part-time job) and perceived
financial situation (good, fair or poor). Participants also completed a bat-
tery of validated questionnaires during the dialysis sessions or while wait-
ing for their regular follow-up visit at the transplant centre.
Laboratory data were extracted from the patients’ charts and from elec-
tronic laboratory databases of hospitals. The following laboratory para-
meters were tabulated: Hb, serum creatinine and albumin. Estimated
glomerular filtration rate (eGFR) was calculated using the 4-variable
Modification of Diet in Renal Disease Study equation [28].
Transplant- and dialysis-related data extracted from the medical re-
cords included the following information: medications (including current
immunosuppressive treatment), single-pool Kt/V, ‘vintage’, i.e. time
elapsed since the time of the transplantation or since starting dialysis
treatment. Cumulative end-stage renal disease (ESRD) time (time
elapsed since the initiation of the first treatment for ESRD) was also
computed.
The study was approved by the Ethics Committee of the Semmelweis
University. Before enrolment, the patients received detailed written and
verbal information regarding the aims and protocol of the study and
signed informed consent.
Assessment of HRQoL
HRQoL was assessed with the KDQoL-SFTM questionnaire which in-
cludes the Medical Outcomes Study Short Form-36 generic core (SF-
36) and several multi-item scales targeted at quality of life concerns with
special relevance for patients with CKD [22]. Scores for each item are
computed in order to gain a potential range from 0 to 100 within each
dimension/domain, with higher scores indicating better HRQoL [29].
The generic core consists of eight multi-item measures of physical and
mental health status, of which four are reported in the present analysis:
‘Physical functioning’, ‘General health perceptions’, ‘Energy/fatigue’
and ‘Emotional well-being’. The kidney disease-targeted domains that
were used in this analysis focus on health-related concerns of individuals
with kidney disease: ‘Symptoms/problems’, ‘Effects of kidney disease on
daily life’, ’Burden of kidney disease’ and ‘Sleep’. These kidney disease-
targeted domains were selected since they were psychometrically sound
both in the original validation studies and in the Hungarian version of the
instrument.
The Hungarian version of the KDQoL has been prepared by the FACIT
translation group which followed the FACIT translation methodology
[30]. We have recently provided evidence that most of the sub-scales of
the Hungarian KDQoL-SFTM are psychometrically sound and reliable both
in dialyzed and transplanted populations [23]. The internal consistency
of the individual sub-scales and test–retest reliability was similar to the
original tool and to other translations.
Assessment of depressive symptoms
In the present analysis, scores obtained with the Center for Epidemiologic
Studies Depression (CES-D) questionnaire were used to describe the se-
verity of depressive symptoms in the sample [31]. The Hungarian version
of the CES-D scale had been prepared according to a recommended pro-
cedure and has been validated by our team in Hungarian haemodialysis
and kidney-transplanted patients [32,33]. Internal consistency was excel-
lent both in transplanted (Cronbach’s alpha = 0.865) and dialysis (Cron-
bach’s alpha = 0.894) patients. We found a very good fit between the
original four-factor structure of the scale (Depressed Affect, Positive
Affect, Somatic Component and Interpersonal) and the data obtained both
from Hungarian haemodialysis and kidney-transplanted patients. Finally,
the CES-D score showed a moderate–strong correlation with other self-
reported measures of emotional well-being, suggesting that the Hungarian
version is a reliable tool to measure depressive symptoms in different
CKD populations.
Self-reported comorbidity and self-reported sleep problems
Information about the presence or absence of comorbid conditions was
obtained from the patients, as described. Self-reported comorbidity score
was calculated by summing up the number of comorbid conditions the
patients reported. Earlier work of our group suggested that this score cor-
relates with mortality and provides valuable information about the overall
clinical condition of the patients [2,12,25,34,35].
Symptoms of RLS were identified by using the RLS questionnaire
(RLSQ). This scale has been validated as a screening instrument for
RLS in sleep clinics [36]. The questionnaire was used in a recent epide-
miologic survey [37] and in our earlier work [12,26,34]. RLS was identi-













fied only if the patient met all the diagnostic criteria. If the questionnaire
was not filled completely or the patient did not follow the instructions, the
scale was not scored and the information was considered missing.
The Athens Insomnia Scale (AIS) was used to identify insomnia [38].
The AIS consists of eight items (score range 0–24, with higher scores
indicating worse sleep). Subjects are asked to grade the severity of their
specific sleep complaints (absent, mild, severe, very severe) only if the
particular complaint occurred at least three times per week during the last
month. A cut-off score of 10 was used to identify patients with clinically
relevant insomnia [12,27].
The risk status for OSA was assessed by using the Berlin Sleep Ap-
noea Questionnaire [39]. This self-administered tool includes 10 ques-
tions regarding the most frequent symptoms and consequences of
OSA. The instrument consists of three major domains: the first domain
is associated with snoring behaviour and the presence of apnoea. The
second domain relates to the consequences of the apnoea, and the third
domain assesses hypertension or high body mass index (BMI) (>30 kg/
m2). An individual is considered to be at ‘high risk’ for OSA if two of
the three main domains are positive. If at least two domains are negative,
the patient is classified as ‘low risk’. If the answers were incomplete or
violated the instructions, the scale was not scored and the data were con-
sidered missing [24].
Statistical analysis
Statistical analysis was carried out using the SPSS 18 software. To com-
pare continuous variables between the Tx vs WL groups, the Student’s t-
test or the Mann–Whitney U-test was used. Categorical variables were
analysed with the chi-square test. To compare QoL scores between WL
vs Tx groups, the Mann–Whitney U-test was used since the distribution
of these variables deviated from normal. To assess the independent asso-
ciation between quality of life scores and RRT, multiple linear regression
models were built. The skewed QoL scores were natural log-transformed.
Independent variables were entered in blocks to assess the relative contri-
bution of group variables to the overall model. RRT (WL or Tx) was the
first block, followed by socio-demographic characteristics (age, gender,
education and self-perceived financial situation) and clinical variables
(Hb, serum albumin, comorbidity and cumulative ESRD vintage), report-
edly associated with HRQoL in various patient populations, in one block.
The presence of the most frequent self-reported sleep problems (insomnia,
RLS and OSAS) was entered as the third block of independent variables
followed by the CES-D score as the fourth block.
Results
Socio-demographic and basic clinical characteristics of
the sample
Quality of life data were not available due to refusal or in-
appropriate completion of the questionnaires for 179
(17%) of the Tx and 27 (13%) of the WL patients (non-
participants). The final sample analysed, therefore, con-
sisted of 888 Tx and 187 WL patients. Participants and
non-participants in both the Tx and the WL groups were
similar in age, gender distribution, serum albumin and cu-
mulative ESRD ‘vintage’, and also had similar eGFR or
Kt/V, respectively (not shown). Non-participant Tx patients
had longer transplant ‘vintage’ compared to participants
[median (inter-quartile range — IQR) 66 (57) vs 54 (64)
months for non-participants vs participants, respectively;
P < 0.001]. All participants were Caucasians.
The basic characteristics of the Tx vs WL groups are
shown in Table 1. Tx patients had significantly longer cu-
mulative ESRD ‘vintage’, higher Hb and higher serum al-
bumin compared to the WL group. Sleep disorders were
more frequent among WL compared to Tx patients, except
high risk of OSAS, as reported by our group [24,26,27]
(Table 1). Similarly, as we have already reported, WL pa-
tients had higher CES-D scores compared to the Tx group,
indicating more severe depressive symptomatology [33].
All other parameters assessed were similar in the two
groups (Table 1). Detailed description of the study sample
has been published in several publications [26,27,33].
HRQoL in WL vs Tx patients
Scores for selected domains of the KDQoL-SF question-
naire for the Tx vs WL groups, respectively, are shown




(n = 187) P-value*
Male — n (%) 515 (58) 112 (60) 0.7
Age (years) (mean ± SD) 49 ± 13 49 ± 12 0.8
Working part- or full-time job — n (%) 231 (26) 45 (24) 0.5
Self-reported financial situation — n (%)
Good or very good 462 (52) 90 (48) 0.5
Balanced 311 (35) 65 (35)
Poor or very poor 115 (13) 32 (17)
Number of years in education — n (%)
<12 years 408 (46) 86 (46) 0.9
High school or equivalent 293 (33) 64 (34)
University diploma 187 (21) 37 (20)
BMI (kg/m2) 24.8 ± 5.2 25.0 ± 4.4 0.2
Diabetes — n (%) 151 (17) 34 (18) 0.8
Number of comorbid conditions (median; min–max) 2; 0–7 2; 0–6 0.9
Transplant or dialysis vintage (months) [median; (IQR)] 54; (64) 36; (46) N/A
Cumulative ESRD time (months) [median; (IQR)] 81; (70) 36; (46) <0.001
Serum albumin (g/L) (mean ± SD) 41.6 ± 3.3 40.8 ± 4.2 0.01
Haemoglobin (mean ± SD) (g/L) 132 ± 19 112 ± 5 <0.001
Kt/V or eGFR (mL/min/1.73 m2) (mean ± SD) 49 ± 19 1.28 ± 0.26 N/A
CES-D score [median; (IQR)] 9 (11) 13 (15) 0.001
Insomnia (yes) — n (%) 71 (8) 28 (15) 0.002
RLS (yes) — n (%) 44 (5) 21 (11) 0.001
High risk of OSAS (yes) — n (%) 240 (27) 62 (33) 0.1













in Table 2. Median scores were significantly higher for the
Tx vs WL groups for all individual sub-scales assessed.
The difference between the Tx vs WL groups was substan-
tial, more than 10 points for most of the domains. Numer-
ically, the largest difference was seen for two of the kidney
disease-targeted dimensions, namely ‘burden’ and ‘effects’
of kidney disease and for the ‘general health perceptions’
sub-scale. The effect size varied between 0.24 (for ‘phys-
ical function’) and 0.90 (‘burden of kidney disease’). The
effect sizes were small for the SF-36 domains, except for
the ‘general health perceptions’ sub-scale, which was 0.65,
and medium–big for the kidney disease-targeted domains,
except for ‘sleep’, which was 0.32 (Table 2).
Multivariate analysis
To assess if renal replacement modality, i.e. dialysis vs
transplant is signif icantly associated with the various
HRQoL domains independent of socio-demographic and
clinical variables, multiple linear regression models were
built, where the logarithmically transformed HRQoL scores
were the dependent variable. Variables which were signifi-
cantly associated with HRQoL in bivariate analyses or had
been reported to be associated with HRQoL by others were
selected for themultivariablemodels. Independent variables
were entered in blocks to assess the relative contribution of
these blocks to the overall model (see ‘Materials and meth-
ods’). The results of these analyses are shown in Table 3.
The first block of independent variables was RRTmodal-
ity alone. In this set of analyses, modality was significantly
associated with all the HRQoL domains assessed in accord
with data shown in Table 2. The adjusted R square for these
models, however, was quite small for most of the domains,
indicating that modality alone explained only 0.4–10% of
the variance of the HRQoL scores (Table 3). Relatively,
the largest effect was seen for the kidney disease-targeted
‘burden’ and ‘effect of kidney disease’ scales and the ‘gen-
eral health perceptions’ scale of the SF-36 instrument.
All the models improved significantly and substantially
after entering socio-demographic characteristics (age, sex,
education, self-reported financial situation) and clinical
variables (serum albumin, Hb, comorbidity, ESRD vin-
tage) as one block. The association between ‘modality’
vs HRQoL remained significant for only five of the eight
domains assessed. Importantly, this association remained
significant for all the kidney disease-targeted dimensions
(Table 3). These models explained ~9–20% of the total
variability of the HRQoL scores. The relative contribution
of this block was the largest for the ‘physical function’
and the ‘general health perception’ domains, but it was
substantial for the kidney disease-targeted scales, as well
(Figure 1).
Table 2. Quality of life scores of WL vs Tx patients
General HRQoL domains (SF-36)
Waiting list (n = 187) Tx (n = 888)
P-value
Effect size
(Cohen’s d)Median IQR Median IQR
Physical functioning 70 35 80 35 0.001 0.24
General health perceptions 35 30 50 40 <0.001 0.65
Emotional well-being 72 36 80 32 0.003 0.25
Energy/fatigue 60 35 70 35 <0.001 0.32
Kidney disease-targeted domains
Symptoms/problems 82 23 89 18 <0.001 0.41
Burden of kidney disease 50 38 75 38 <0.001 0.90
Effects of kidney disease 69 28 87 25 <0.001 0.70
Sleep 65 30 75 28 <0.001 0.32
Table 3. Multivariate linear regression analysis of quality of life domains (Ln-transformed scores) to assess the association with RRT modality
A: modality B: A+ Block 2 C: B+ Block 3 D: C+ Block 4
Beta P-value
Adjusted
R square Beta P-value
Adjusted
R square Beta P-value
Adjusted
R square Beta P-value
Adjusted
R square
physfctn 0.068 0.04 0.004 0.036 0.3 0.198 0.019 0.6 0.258 0.005 0.9 0.309
genhealth 0.225 <0.001 0.050 0.195 <0.001 0.175 0.173 <0.001 0.228 0.158 <0.001 0.290
energy 0.110 0.001 0.011 0.082 0.2 0.116 0.057 0.09 0.222 0.027 0.3 0.479
emotional 0.065 0.5 0.003 0.059 0.09 0.109 0.033 0.3 0,193 −0.001 0.9 0.510
sympt 0.124 <0.001 0.014 0.092 0.008 0.144 0.067 0.05 0.214 0.038 0.1 0.321
burden 0.321 <0.001 0.102 0.263 <0.001 0.180 0.241 <0.001 0.233 0.219 <0.001 0.364
effects 0.230 <0.001 0.052 0.228 <0.001 0.148 0.200 <0.001 0.222 0.182 <0.001 0.313
sleep 0.117 <0.001 0.013 0.095 0.008 0.092 0.042 0.2 0.361 0.024 0.4 0.455
Shown in the cells are the parameters of the independent variable: waiting list vs transplantation. Independent variables entered into the model: Block 1:
modality; Block 2 (clinical and socio-demographic): age, gender, education, self-reported financial situation, serum albumin, haemoglobin, number of
comorbid conditions, ESRD vintage; Block 3 (sleep disorders): self-reported restless legs syndrome, obstructive sleep apnoea, insomnia; Block 4:
depressive symptoms (CES-D score).
Abbreviations: physfctn, physical function; genhealth, general health perceptions; energy, energy-fatigue; emotional, emotional well-being; sympt,
symptoms/problems list; burden, burden of kidney disease; effects, effects of kidney disease; sleep, sleep.
Highlighted with bold when the association between HRQoL domain and RRT modality is statistically significant.













Entering the ‘sleep problem’ block (the presence of self-
reported insomnia, RLS or high risk of OSAS) was asso-
ciated with an R squared change ~0.05–0.10, which corre-
sponds to ~20% of the variance of the fully adjusted
models, except for the sub-scale of ‘sleep’. The ‘sleep
problem’ block explained ~60% of the variance of this do-
main (Table 3 and Figure 1), and the association between
‘modality’ and the ‘sleep’ score has expectedly become
non-significant after controlling for the presence of ‘sleep
problems’ (Table 3).
The fully adjusted models (which included the CES-D
score in addition to the previous blocks) explained be-
tween 29% (‘general health’) and 0.51% (‘emotional
well-being’) of the variance of the quality of life scores
(Table 3). The relative contribution of the CES-D score
to the overall variance was above 40% for most of the gen-
eral HRQoL dimensions and 20–30% for the kidney dis-
ease-targeted domains (Figure 1). In the f inal, fully
adjusted model ‘modality’ was still significantly asso-
ciated with one of the four general HRQoL domains (‘gen-
eral health perceptions’) and two of the four kidney
disease-targeted dimensions (‘burden’ and ‘effect’ of kid-
ney disease) (Table 3).
Discussion
In this study, we found significantly better HRQoL in a
large sample of kidney transplant recipients compared to
a group of WL haemodialysis patients with very similar
characteristics. This difference, however, has become
non-significant in three out of the four generic HRQoL do-
mains of the SF-36 instrument after adjusting for socio-
demographic and clinical variables. Importantly, kidney
disease-targeted sub-scales of the KDQoL-SF question-
naire persistently yielded significantly better HRQoL for
the Tx patients even after adjusting for the presence of
sleep disorders and difference in depressive symptoms.
These results confirm that kidney transplantation is asso-
ciated with better HRQoL compared to dialysis. We also
demonstrated the complexity of HRQoL assessment and
emphasize the need of using multifaceted approach when
comparing HRQoL data between groups of patients treated
with different treatment modalities.
There seems to be a general consensus that kidney trans-
plantation improves quality of life compared to dialysis
treatment [6–8,18]. Data from numerous, predominantly
cross-sectional studies seemed to support this notion. Most
of those studies, however, used non-selected patients on
maintenance dialysis as comparator group and did not con-
trol for potentially important differences in case mix be-
tween patients after kidney transplantation vs on dialysis
treatment. The importance of this is clearly pointed out
by the result of the recent meta-analysis which suggested
that the difference in HRQoL measured by the SF-36 in-
strument between kidney transplant recipients vs patients
on dialysis was substantially reduced after controlling for
age and diabetes [18]. Furthermore, Rosenberger et al.
found no difference in HRQoL between groups of WL
and Tx patients matched for age, gender and comorbidity
[19]. Our results are in accord with these published data
and extend our understanding further. The basic socio-













Quality of life dimension
%
Fig. 1. Relative contribution of blocks of independent variables to the fully adjusted R squared of the HRQoL domains. Modality: Tx or WL; Clin-S/d
(clinical and socio-demographic): age, gender, education, self-reported financial situation, serum albumin, haemoglobin, number of comorbid
conditions, ESRD vintage; Sleep (sleep disorders): self-reported restless legs syndrome, obstructive sleep apnoea, insomnia; Depression: depressive
symptoms (CES-D score). Abbreviations: Phy fctn, physical function; Gen H, general health perceptions; Energy, energy-fatigue; emotional, emotional
well-being; symptoms, symptoms/problems list; Burden, burden of kidney disease; Effects, effects of kidney disease; Sleep, sleep.













demographic and clinical characteristics of our large sam-
ples of Tx and WL patients were very similar. Both generic
and kidney disease-targeted HRQoL dimensions were sig-
nificantly better in the Tx group, but RRT modality ac-
counted for only a small proportion of the variance of
the HRQoL scores. After adjusting for socio-demographic
and clinical variables, the HRQoL scores on the generic
sub-scales were not associated with modality any more,
except the ‘general health perception’ sub-scale (which
was not assessed in the paper of Rosenberger et al.). These
results point out that even seemingly similar groups of pa-
tients will have subtle differences which influence the
comparison between those groups. Importantly, the vari-
ance explained by these models (including RRT modality
and eight additional variables) was only 10–20%.
Sleep disorders, namely RLS, insomnia and OSA, are
prevalent among patients with CKD and are reportedly as-
sociated with HRQoL both in patients on dialysis and after
Tx. Our WL population is characterized by lower preva-
lence of sleep disorders compared to previous reports
[40–42]. One possible explanation for this is that our
WL dialysis population is younger and healthier than the
non-selected prevalent HD populations involved in other
studies. The prevalence of insomnia reportedly increases
with age and also with comorbidity [43]. Secondly, the
methods used to assess sleep problems may result in differ-
ences in the reported prevalence. In this study, we used
standard instruments and stringent criteria to define the
sleep problems assessed.
Similarly to insomnia, the difference in the prevalence of
RLS in this paper compared to previous reports is likely
explained by sample characteristics. The prevalence of
RLS defined by the criteria of the International Restless
Legs Syndrome Study Group in maintenance dialysis po-
pulations is 7–23% [11,41,42]. Using the RLSQ, our group
has found 15% RLS in a prevalent dialysis population
while the prevalence of RLS was 11% in WL patients
[12]. This latter is similar to the prevalence of the condition
reported by Merlino et al. for non-dialysis dependent-CKD
patients [44]. The prevalence of sleep conditions is gener-
ally less among kidney transplant recipients compared to
patients on maintenance dialysis [26,27,40,45]. Having
self-reported sleep problems in the multivariable models
did not seem to account for the difference between the
Tx and WL groups, at least for three sub-scales (the strong
association between the presence of sleep disorders and the
‘sleep’ sub-scale was expected).
Depression is a powerful predictor of quality of life
[46–48]. Both clinically diagnosed depression and the pres-
ence of depressive symptoms have repeatedly been shown
to be associated with impaired HRQoL in various patient
populations. Depressive symptoms are frequently present
in patients on dialysis, and their severity and/or prevalence
decreases after kidney Tx [33,49]. The CES-D score in our
final set of multivariable models explained ~20–30% of the
total variance of the HRQoL scores not directly associated
with mood. Importantly, the association between ‘modality’
and the HRQoL scores remained consistently significant in
the three sub-scales mentioned previously (‘general health
perceptions’, ‘effects’ and ‘burden’ of kidney disease) even
after adjusting for differences in depressive symptoms.
These results clearly demonstrate that several aspects of
quality of life, specifically generally feeling ‘healthy’ and
also more specifically kidney disease-related concerns, are
better in kidney transplant recipients even after extensive
adjustment for socio-demographic, clinical characteristics
and even sleep problems and depressive symptoms.
As indicated earlier, the three HRQoL dimensions that
are robustly and consistently better in the Tx vs WL
groups were ‘general health perceptions’, ‘effects’ and
‘burden’ of kidney disease. The first dimension combines
notions about ‘feeling healthy’ in general and compared to
others, and also about expectations about one’s future
health. The better HRQoL of the Tx patients on this sub-
scale is likely a reflection of the difference between the
perceptions of being a ‘transplanted patient’ vs a ‘patient
on dialysis’. The ‘objective health status’ of the WL pa-
tients may be very similar to their transplanted counter-
parts; the subjective perception of one’s own health is
largely influenced by their very different treatment modal-
ity and treatment environment.
Renal transplantation is not a uniformly and exclusively
positive experience for all patients. Factors related to the
kidney disease, such as medication side effects, psycho-
social distress, anxiety, employment problems [5], are still
present and have a negative impact on quality of life.
Transplanted patients, however, still perceive less interfer-
ence of their condition with valued everyday activities and
are less concerned about their condition compared to WL
patients as indicated by the significantly better scores on
the ‘effects’ and ‘burden’ of kidney disease sub-scales.
These are particular areas of quality of life which are
not captured by the generic instruments. These results
underline the need for disease-specific instruments when
assessing QoL in patients with CKD.
Our study is notable for the large sample size, well-
matched groups. Numerous clinical, socio-demographic
parameters were collected. Importantly, rarely assessed
psycho-social characteristics and sleep problems were
also recorded and used in the multivariable models.
The multidimensional nature of the KDQoL-SF instru-
ment allowed us to analyse specific aspects of HRQoL
and also the relative contribution of various sets of inde-
pendent variables to these individual dimensions of qual-
ity of life.
Several important limitations of our study should also be
noted when interpreting the results. Patients from a single
centre were enrolled; therefore, our results are not to be gen-
eralized without further considerations. Generalizability is
further limited, particularly as compared with the US
CKD population, because of the relatively young age, low
percentage of diabetics, lack of African-Americans or other
ethnic groups and the low number of comorbid conditions in
our sample.
The cross-sectional nature of our study does not allow
us to conclude about the temporality or a causal relation-
ship between treatment modality and HRQoL.
The proportion of non-participants was substantial.
These patients, however, had similar socio-demographic
characteristics to those who completed the questionnaire;
consequently, it is unlikely that this has caused a system-
atic bias in our results.













Depressive symptoms and the presence of sleep disor-
ders were assessed by self-reported scales, which does
not allow us make clinical diagnosis. Questionnaires, on
the other hand, remain valuable tools in large scale epide-
miologic studies. Our earlier results suggest that the Hun-
garian version is a reliable tool to measure depressive
symptoms in different CKD populations [3,32,33].
Information about comorbid conditions was based on self-
report of the patients. However, elements of the ESRD-SI, a
valid comorbidity questionnaire [36], were integrated into
our tool. In a cross-sectional analysis, the self-reported
comorbidity score was significantly correlated with serum
albumin [37]. Self-reported comorbidity was also signifi-
cantly associated with mortality in this patient population
[38]. We suggest, therefore, that this score provides valu-
able information about the overall clinical condition of
the patients.
Conclusion
In summary, we reported here that several, but not all,
dimensions of HRQoL were significantly better in a large
sample of kidney transplant recipients compared to a
well-matched group of WL haemodialysis patients after
extensive adjustment for socio-demographic, clinical and
psycho-social characteristics. The most substantial differ-
ence between the two groups was seen in kidney disease-
targeted sub-scales of the KDQoL-SF questionnaire.
These results demonstrate the complexity of HRQoL as-
sessment and emphasize the need of using a multifaceted
approach when comparing HRQoL data between groups
of patients treated with different treatment modalities.
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Abstract
Background. The influence of acute graft pyelonephritis
(AGPN) on graft outcome in renal transplant recipients
still remains controversial.
Methods. We retrospectively analysed 189 patients (113
males; mean age: 49.7 ± 13.1 years) undergoing renal
transplantation at the University Hospital 12 de Octubre
(Madrid, Spain) from January 2002 to December 2004,
with a minimum follow-up of 36 months. Factors asso-
ciated with AGPN were assessed by logistic regression
analysis. Long-term graft function was compared according
to the occurrence of this complication during follow-up.
‘Decline in renal graft function’ was defined as the increase
in serum creatinine (SC) levels >0.33 mg/dL between
Month 3 and Year 1 after transplantation.
Results. Nineteen patients (10.0%) were diagnosed with
25 episodes of AGPN (incidence rate: 4.4 episodes per
100 patient-years). The presence of glomerulonephritis
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